Back to Search Start Over

Supplementary Data from Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....3cee480ac1ee5f0a60ca406c3be2c3bc
Full Text :
https://doi.org/10.1158/1078-0432.22473104